Analystreport

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was upgraded by analysts at Credit Suisse Group AG to a "buy" rating. They now have a $15.00 price target on the stock.

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com